Results 41 to 50 of about 70,330 (230)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab. [PDF]

PLoS ONE, 2017
The EGFR-specific mAb cetuximab is one of the most effective treatments for oropharyngeal carcinoma, while patient responses to EGFR inhibitors given alone are modest.
Chaonan Sun, Chuyang Han, Yuanjun Jiang, Ning Han, Miao Zhang, Guang Li, Qiao Qiao   +6 more
doaj   +1 more source

The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab

Laboratory Animal Research, 2018
This study investigated the anti-cancer potential of a near-infrared fluorescence (NIRF) molecule conjugated with Cetuximab (Cetuximab-NIRF) in six-week-old female BALB/c athymic (nu+/nu+) nude mice. A431 cells were cultured and injected into the animals
Ji Young Yun, Byung-Hwa Hyun, Sang Yoon Nam, Young Won Yun, Hu-Jang Lee, Beom-Jun Lee   +5 more
doaj   +1 more source

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. [PDF]

, 2010
Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth.
Bigner, DD, Chiosea, SI, Gooding, WE, Grandis, JR, Kuan, C-T, Lai, SY, Leeman-Neill, RJ, Sen, M, Suzuki, S, Thomas, SM, Wheeler, SE   +10 more
core  

EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]

, 2018
A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico, Gazzaniga, Paola, Raimondi, Cristina, Urbano, Federica   +3 more
core   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Harreus, Ulrich, Reiter, Maximilian, Schwenk-Zieger, Sabina   +3 more
core   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan, Burtness, Barbara, Cheng, Jonathan D, Chow, Laura QM, Chung, Hyun Cheol, Dolled-Filhart, Marisa, Eder, Joseph Paul, Geva, Ravit, Gupta, Shilpa, Haddad, Robert, Kang, Hyunseok, Keam, Bhumsuk, Lee, Se-Hoon, Lin, Chia-Chi, Mahipal, Amit, Mehra, Ranee, Meister, Amy, Muro, Kei, Pathiraja, Kumudu, Seiwert, Tanguy Y, Tahara, Makoto, Weiss, Jared   +21 more
core   +2 more sources